Related Experiment Video

Updated: May 21, 2026

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion
09:23

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion

Published on: April 2, 2020

Knockdown of CDK6 enhances glioma sensitivity to chemotherapy

Bing Li1, Hua He, Bang-Bao Tao

  • 1Department of Neurosurgery, Changzheng Hospital, Second Affiliated Hospital of Second Military Medical University, Shanghai 200003, PR China.

Oncology Reports
|June 28, 2012
PubMed

Insights

Cyclin-dependent kinase 6 (CDK6) is upregulated in glioma, driving tumor growth and chemotherapy resistance. Inhibiting CDK6 enhances chemotherapy effectiveness by increasing apoptosis and reducing drug resistance genes.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Glioma is a primary brain tumor with poor prognosis.
  • Chemotherapy is a standard treatment, but resistance is a major challenge.
  • Molecular mechanisms of glioma chemotherapy resistance are poorly understood.

Purpose of the Study:

  • To investigate the role of CDK6 in glioma chemotherapy resistance.
  • To explore CDK6 as a potential therapeutic target for overcoming resistance.

Main Methods:

  • Analysis of CDK6 expression in glioma tissues.
  • shRNA-mediated CDK6 knockdown in U251 glioma cells.
  • Assessment of cell proliferation, apoptosis, and drug resistance gene expression.

Main Results:

  • CDK6 is upregulated in glioma, correlating with malignancy grade.
  • CDK6 knockdown inhibits glioma cell proliferation and survival.
  • CDK6 inhibition increases temozolomide-induced apoptosis.
  • CDK6 knockdown reduces expression of drug resistance genes (MRP, MDR).

Conclusions:

  • CDK6 is a key mediator of glioma resistance to chemotherapy.
  • Targeting CDK6 represents a promising strategy to enhance chemotherapy efficacy.
  • CDK6 inhibition can sensitize glioma cells to standard chemotherapeutic agents.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...